{"id":"W4401354990","doi":"10.1016/j.esmoop.2024.103647","title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"Eli Lilly Japan; Sirtex Medical; Ipsen; Kaohsiung Medical University Chung-Ho Memorial Hospital; Teijin Pharma; Japanese Society of Medical Oncology; European Society for Medical Oncology; Health Promotion Administration, Ministry of Health and Welfare; Kaohsiung Medical University; Chunghwa Telecom Laboratories; ReShape Lifesciences; Genentech; Veracyte; Astellas Pharma; Eisai; Fondazione Beretta; BeiGene; Handok; Les Laboratories Pierre Fabre; Pfizer; Incyte; Boehringer Ingelheim Japan; Taiho Pharmaceutical; Chugai Pharmaceutical; Abbott Japan; AstraZeneca; Invitae; Yuhan; Daiichi Sankyo Europe; Servier; Gilead Sciences; Halozyme; Exelixis; Sanofi; Relay Therapeutics; Amgen; Rakuten Medical; Celgene; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Biliary tract cancer; Cancer; Medicine; Biliary tract; Clinical Practice; General surgery; Internal medicine; Family medicine; Gemcitabine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02184765,0.001138809,0.001723698,0.004495504,0.001184051,0.003198703,0.002890136,0.004875288,0.007334548],"category_scores_gemma":[0.05992137,0.0007368971,0.00389174,0.004085166,0.001323596,0.002027236,0.003555252,0.005465386,0.007478734],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003849409,"about_ca_system_score_gemma":0.0195324,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01339984,"about_ca_topic_score_gemma":0.02321286,"domain_scores_codex":[0.9742149,0.01223918,0.007426945,0.0008953518,0.004310545,0.000912988],"domain_scores_gemma":[0.946974,0.008177887,0.005811558,0.001739783,0.0354536,0.001843071],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003521479,0.0002226196,0.005722563,0.009739922,0.0003539576,0.0008756147,0.001527286,0.001174318,0.001717675,0.00745521,0.7085017,0.2623569],"study_design_scores_gemma":[0.0002683702,0.000175834,0.01114257,0.02264381,0.0002859306,0.001668973,0.0008234768,0.0008016899,0.0006269235,0.006282893,0.9551538,0.0001258027],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"review","genre_scores_codex":[0.01280111,0.2007207,0.1357377,0.3585991,0.03946375,0.0201542,0.03063375,0.00254118,0.1993486],"genre_scores_gemma":[0.08240818,0.223814,0.3886988,0.1304461,0.0117649,0.03439521,0.05854334,0.001342423,0.06858696],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.02184765,"threshold_uncertainty_score":0.1155428,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1414069728864935,"score_gpt":0.4450970365877709,"score_spread":0.3036900637012774,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}